LARIMAR THERAPEUTICS INC

Insider buys 50,000 shares of Larimar Therapeutics, signaling confidence in its rare‑disease pipeline, tech edge, and growing payer prospects.

Insider buying spurs optimism for Larimar Therapeutics’ rare‑disease pipeline, hinting at undervalued growth amid clinical milestones and market access challenges.

Insider buying spurs curiosity about Larimar Therapeutics’ rare‑disease pipeline – explore the implications for investors and the biotech’s future.

Larimar Therapeutics insiders buy zero‑cost options tied to board tenure, showing confidence amid governance changes and share‑count expansion—watch for dilution and clinical milestones.

Flynn James E. buys 4M shares of Larimar Therapeutics at $5—an insider confidence boost amid strong gains, yet concentration may spark future sell‑off risk.

Insider buying at Larimar Therapeutics signals confidence in its rare‑disease pipeline, market‑access strategy and financial strength—an optimistic outlook for investors.

Insider buying at Larimar Therapeutics signals management confidence amid market volatility – learn why executives are staking on LAR‑001’s breakthrough potential.